Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are currently being prescribed Jyseleca (filgotinib) tablets in South Korea, following the approved guidelines for its use there.
- You have moderate to severe rheumatoid arthritis as an adult, and previous treatments (called DMARDs) have not worked well enough for you or caused side effects you could not tolerate.
- You have moderate to severe ulcerative colitis as an adult, and previous treatments (such as steroids, immune-suppressing medicines, or biological medicines) have not worked, stopped working, or caused side effects you could not tolerate.
- If you are over 65, have a high risk of heart disease, or have a history of cancer, you may still be considered, but only if other treatments have not worked or have not been tolerated (confirm with trial site).
Who may not be able to join:
- You have a known allergy or sensitivity to any ingredient in the Jyseleca tablet.
- You currently have an active infection of any kind, including serious infections like blood poisoning (sepsis), or a local infection.
- You currently have active tuberculosis (TB).
- You have severe liver disease.
- You have end-stage kidney disease (kidneys that are failing completely).
- Your blood test results show that certain blood cell levels are too low — specifically, your white blood cells (neutrophils), immune cells (lymphocytes), or red blood cells (haemoglobin) fall below certain limits (confirm exact values with trial site).
- You are pregnant, possibly pregnant, or currently breastfeeding.
- You have certain rare inherited conditions affecting how your body handles sugars, such as galactose intolerance or glucose-galactose malabsorption, because the tablet contains lactose.
- You are already taking part in another clinical study involving filgotinib (the active ingredient in Jyseleca).
- The doctor running the trial considers your participation unsuitable for any other medical reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-2-3451-5533
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Serious Adverse Events (SAEs); Number of Participants With Adverse Drug Reactions (ADRs); Number of Participants With Unexpected AEs; Number of Participants With Unexpected ADRs; Number of Participants With Known ADRs; Number of Participants With Non-serious AEs; Number of Participants With Non-serious ADRs; Change From Baseline in Disease Activity Score 28 Based on C-Reactive Protein (DAS28-CRP) at Week 12 and Week 24; Change From Baseline in the Mayo Clinic Score (MCS) at Week 12 and Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.